DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): AGM/EGM 
Newron announces AGM 2021 result 
2021-04-13 / 12:00 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Newron announces AGM 2021 result 
Milan, Italy - April 13, 2021 - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical 
company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous 
system, announced that its shareholders approved the sole motion on the agenda of the AGM 2021 held today, being the 
approval of the Company's balance sheet as of 31 December 2020 (including related and consequent resolutions). 
About Newron Pharmaceuticals 
Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for 
patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, 
Italy. Xadago^(R)/safinamide has received marketing authorization for the treatment of Parkinson's disease in the 
European Union, Switzerland, the USA, Australia, Canada, Brazil, Colombia, Israel, the United Arab Emirates, Japan and 
South Korea, and is commercialized by Newron's Partner Zambon. Supernus Pharmaceuticals holds the commercialization 
rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian 
territories. Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients 
with positive symptoms of schizophrenia. For more information, please visit: www.newron.com 
For more information 
Newron 
Stefan Weber - CEO 
+39 02 6103 46 26 
pr@newron.com 
UK/Europe 
Simon Conway/ Natalie Garland-Collins, FTI Consulting 
SCnewron@fticonsulting.com 
Switzerland 
Valentin Handschin, IRF Reputation 
+41 43 244 81 54 
handschin@irf-reputation.ch 
Germany/Europe 
Anne Hennecke/Caroline Bergmann, MC Services 
+49 211 52925220 
newron@mc-services.eu 
USA 
Paul Sagan, LaVoieHealthScience 
+1 617 374 8800, Ext. 112 
psagan@lavoiehealthscience.com 
=---------------------------------------------------------------------------------------------------------------------- 
2021-04-13 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=----------------------------------------------------------------------------------------------------------------------

1184059 2021-04-13

(END) Dow Jones Newswires

April 13, 2021 06:00 ET (10:00 GMT)